ProQR Therapeutics N.V. — FY2017 Form 20-F
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing. Financial statements are audited and prepared under IFRS as issued by the IASB; amounts below are in euros unless stated otherwise.
Business context
ProQR is a clinical-stage biopharmaceutical company developing RNA-based treatments for rare genetic diseases. It had no marketed products and generated no product or royalty revenue. Its reported other income consisted mainly of grants and sublease income. Key programs included eluforsen for cystic fibrosis (CF), QR-110 for LCA10, QR-313 for dystrophic epidermolysis bullosa (DEB), and preclinical ophthalmology and RNA-editing programs.
Key financial metrics
| Metric | FY2017 / December 31, 2017 | Prior comparable period |
|---|---|---|
| Other income | €1.495 million | €1.828 million in FY2016 |
| Research and development costs | €31.153 million | €31.923 million in FY2016 |
| General and administrative costs | €10.840 million | €9.478 million in FY2016 |
| Operating loss | €40.498 million | €39.573 million in FY2016 |
| Net loss | €43.675 million | €39.103 million in FY2016 |
| Basic and diluted loss per share | €1.72 | €1.67 in FY2016 |
| Net cash used in operating activities | €34.951 million | €34.221 million in FY2016 |
| Cash and cash equivalents | €48.099 million | €59.200 million at December 31, 2016 |
| Total assets | €53.103 million | €65.543 million at December 31, 2016 |
| Total liabilities / total equity | €13.778 million / €39.325 million | €12.407 million / €53.136 million at December 31, 2016 |
| Borrowings | €7.244 million | €5.697 million at December 31, 2016 |
The company reported no sales revenue, so a sales-based margin is not meaningful. FY2017 financing cash inflow was €26.640 million, principally from share issuance; investing cash outflow was €0.121 million. Cash declined by €11.101 million during the year, including a €2.669 million adverse currency effect. Management estimated available cash would fund planned operations into the second half of 2019, subject to assumptions and spending needs.
Changes versus FY2016
- Net loss increased by €4.572 million, about 12%; operating loss increased by €0.925 million.
- R&D expense fell by €0.770 million, while G&A expense rose by €1.362 million. Management attributed the R&D mix partly to completion of eluforsen studies and spending on QR-110 and QR-313 clinical work.
- Finance result shifted from €0.470 million income to €3.175 million expense, mainly reflecting foreign-exchange losses on U.S.-dollar cash balances.
- Cash fell by €11.101 million despite €25.685 million of net proceeds from share issuance and €0.650 million from convertible loans.
- Borrowings increased, and €1.960 million was classified as current at year-end. Equity decreased to €39.325 million, reflecting the annual loss partly offset by equity financing.
Outlook, commentary, and material risks
- Funding and cash burn: ProQR expected continued significant losses and no product revenue for the foreseeable future. It stated that cash was expected to support operations into the second half of 2019, but warned that actual needs could be higher and additional financing might not be available on acceptable terms.
- Development plans: Management planned a Phase 2 eluforsen study in 2018, subject to obtaining a partner; six-month QR-110 trial data were expected in 2018 and twelve-month data in 2019; and a Phase 1/2 QR-313 study was planned for 2018. These were forward-looking plans, not reported outcomes.
- Clinical evidence: Preliminary 2017 eluforsen results showed the treatment was reported as well tolerated, with clinically meaningful respiratory-symptom improvements versus placebo in three of four multiple-dose groups and a supportive lung-function trend. The filing also reported no changes in weight gain or sweat chloride; the trial was not powered for statistical significance on exploratory efficacy endpoints.
- Contingent payments: A first commercial sale of eluforsen could trigger up to approximately $16 million in payments to CFFT, with other sales- or transaction-related amounts also possible. A February 2018 agreement provides $7.5 million of FFB funding for QR-421a and could trigger up to $37.5 million in milestone payments after first commercial sale, plus a potential transaction-related payment. These are contingent obligations, not current-period expenses.
- Other obligations: R&D commitments were €7.704 million at year-end, of which €6.094 million was due in 2018; non-cancellable operating lease commitments totaled €4.919 million. The company disclosed no off-balance-sheet arrangements and no material pending legal proceedings as of December 31, 2017.
- Principal risks: The business depends on unproven clinical-stage candidates, regulatory approval, external manufacturers and research organizations, licensed intellectual property, and future financing. Other cited risks include competition, foreign-exchange exposure, reimbursement and pricing uncertainty, and potential dilution. No cash dividends were anticipated in the foreseeable future.
- Audit and controls: Deloitte issued an unmodified audit opinion on the IFRS financial statements. Management reported effective disclosure controls and internal control over financial reporting at year-end; the auditor did not attest to internal control, consistent with the company’s emerging-growth-company status.
Important facts for investors to verify
- Confirm the latest cash position, burn rate, and whether financing or partnerships extend the runway beyond management’s second-half-2019 estimate.
- Check actual progress and results against the stated clinical timelines, particularly the eluforsen Phase 2 plan and QR-110 and QR-313 data milestones.
- Review the terms, triggers, timing, and potential funding impact of CFFT and FFB payments, along with the R&D commitments and debt maturities.
- Assess whether reported eluforsen exploratory results are supported by subsequent, adequately powered clinical data and are clinically meaningful.
- Reconcile share counts when assessing dilution: the filing reports 31,921,865 ordinary shares outstanding at period-end, while the financial statements report 36,425,014 issued shares including 4,503,149 treasury shares.
- Consider the sensitivity of the cash balance and reported results to exchange rates, and the company’s reliance on grant funding, equity issuance, and third parties.